Mechanistic Basis for Maximally Efficacious Dose of Pembrolizumab

Clin Pharmacol Ther. 2022 May;111(5):994. doi: 10.1002/cpt.2492. Epub 2021 Dec 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols*
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab